In contrast to our discovery, in a pooled analysis of four prospective clinical trials including 2,310 early breast cancer patients, Denkert et al. demonstrated that HER2‐low patients had significantly longer survival than HER2‐0 patients.10 The gene discussed is ERBB2; the disease is breast cancer.